Inflazome Limited
Monday, 12 September 2016
ByrneWallace acted for Inflazome Limited in connection with its recent Series A financing round for up to €15 million, which was led by venture capital firms Novartis Venture Funds and Fountain Healthcare Partners.
Inflazome is developing inhibitors of the inflammasome, a compelling biological target that regulates our innate immune response, now associated with a wide variety of diseases. In addition to assisting on the financing round, ByrneWallace advised on a licence agreement between UniQuest Pty Limited (the commercialisation arm of the University of Queensland), Trinity College Dublin and Inflazome.
For further information on this transaction, please visit http://inflazome.com.
The ByrneWallace team who advised on this transaction included Colin Sainsbury (Partner and Head of Life Sciences Group).
